Good Dividend Potential for AbbVie in a Tough Landscape
The narrow-moat firm is undervalued and well-positioned with its dividend.
Stocks
Featured
Reassuring Data Boosts Our Biogen Valuation
Details on Alzheimer's drug candidate are encouraging, but uncertainty remains.
Hostess Stocks Up on Cookies
We like the deal with Voortman and think the shares are undervalued.
How Accenture Keeps Its Moat
The IT services company has a large, dedicated customer base.